Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM OTCMKTS:ETST NASDAQ:IMMX NYSEMKT:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$1.97-10.9%$1.48$0.46▼$7.49$11.84M-0.120.92 million shs494,335 shsETSTEarth Science Tech$0.20$0.19$0.00▼$0.25$58.86M1.9584,032 shs140,604 shsIMMXImmix Biopharma$2.22-3.1%$2.49$1.26▼$3.20$66.03M0.28272,024 shs148,427 shsPHGEBiomX$0.54-27.3%$0.47$0.34▼$2.40$14.32M1.42347,190 shs53,300 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-10.86%-25.38%+18.67%+118.65%-37.06%ETSTEarth Science Tech0.00%-4.76%+11.11%+42.86%0.00%IMMXImmix Biopharma-3.06%+1.37%-19.27%-4.72%0.00%PHGEBiomX-3.07%-0.56%+34.25%+11.88%-61.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group1.0743 of 5 stars0.02.00.00.04.11.70.6ETSTEarth Science TechN/AN/AN/AN/AN/AN/AN/AN/AIMMXImmix Biopharma3.2753 of 5 stars3.35.00.00.01.93.30.6PHGEBiomX2.0049 of 5 stars3.50.00.00.01.10.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/AETSTEarth Science Tech 0.00N/AN/AN/AIMMXImmix Biopharma 2.50Moderate Buy$7.00215.32% UpsidePHGEBiomX 3.00Buy$21.003,810.61% UpsideCurrent Analyst Ratings BreakdownLatest PHGE, APM, ETST, and IMMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025IMMXImmix BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K24.51N/AN/A$2.20 per share0.90ETSTEarth Science Tech$33.12M1.78$0.01 per share17.28$0.01 per share20.00IMMXImmix BiopharmaN/AN/AN/AN/A$0.16 per shareN/APHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/AN/AETSTEarth Science Tech$3.25MN/A0.00∞N/A7.93%72.31%41.28%11/13/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.77N/AN/AN/AN/A-205.35%-110.63%11/11/2025 (Estimated)PHGEBiomX-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/ALatest PHGE, APM, ETST, and IMMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q1 2025IMMXImmix Biopharma-$0.21-$0.22-$0.01-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22ETSTEarth Science Tech0.010.910.67IMMXImmix BiopharmaN/A1.231.23PHGEBiomX0.512.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%ETSTEarth Science TechN/AIMMXImmix Biopharma11.26%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%ETSTEarth Science Tech24.90%IMMXImmix Biopharma55.40%PHGEBiomX1.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableETSTEarth Science Tech3294.30 million221.02 millionNot OptionableIMMXImmix Biopharma928.83 million12.86 millionOptionablePHGEBiomX12026.53 million44.04 millionNot OptionablePHGE, APM, ETST, and IMMX HeadlinesRecent News About These CompaniesBiomX (NYSEMKT:PHGE) Stock Price Down 25.4% - What's Next?August 27 at 3:01 AM | americanbankingnews.comBiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic FibrosisAugust 19, 2025 | globenewswire.comBiomX Posts Q2 Loss With 14% Cost DropAugust 14, 2025 | aol.comABiomX Inc. (PHGE) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comBiomX Reports Second Quarter 2025 Financial Results and Provides Program UpdatesAugust 13, 2025 | globenewswire.comWhat to Expect from BiomX's EarningsAugust 12, 2025 | benzinga.comBiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025August 6, 2025 | globenewswire.comBiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapyJuly 14, 2025 | investing.comBiomX Shares Surge 60% Following Start of Phase 2b Trial for Cystic Fibrosis TreatmentJuly 14, 2025 | msn.comPHGE | BiomX Inc. Stock Overview (U.S.: NYSE American) | Barron'sJuly 14, 2025 | barrons.comBiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic FibrosisJuly 14, 2025 | globenewswire.comBiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic FibrosisJuly 8, 2025 | globenewswire.comBiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 ConferenceMay 21, 2025 | nasdaq.comBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceMay 19, 2025 | globenewswire.comBiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comBiomX Inc. (PHGE) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesMay 15, 2025 | globenewswire.comBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025May 8, 2025 | globenewswire.comBiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 18, 2025 | zacks.comBiomX announces going concern qualification from independent auditApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePHGE, APM, ETST, and IMMX Company DescriptionsAptorum Group NASDAQ:APM$1.97 -0.24 (-10.86%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.27%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Earth Science Tech OTCMKTS:ETST$0.20 0.00 (0.00%) As of 08/29/2025 03:59 PM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Immix Biopharma NASDAQ:IMMX$2.22 -0.07 (-3.06%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.22 +0.00 (+0.23%) As of 08/29/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.BiomX NYSEMKT:PHGE$0.54 -0.20 (-27.33%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$0.54 0.00 (-0.19%) As of 08/29/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
